Top Page
Tong Ren Tang Technologies Co
(1666)
Tong Ren Tang Technologies Co (1666) vs. iShares MSCI Hong Kong ETF (EWH)
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Tong Ren Tang Technologies Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.95B | 7.26B | 6.77B | 5.99B | 5.40B | 4.61B |
| Gross Profit | 2.77B | 2.88B | 2.85B | 2.59B | 2.29B | 2.07B |
| EBITDA | 1.11B | 1.17B | 1.30B | 1.39B | 1.26B | 1.14B |
| Net Income | 431.71M | 521.79M | 590.19M | 582.89M | 507.25M | 467.55M |
Balance Sheet | ||||||
| Total Assets | 14.54B | 14.41B | 13.51B | 12.48B | 11.59B | 10.94B |
| Cash, Cash Equivalents and Short-Term Investments | 5.15B | 4.38B | 4.24B | 4.18B | 3.89B | 3.49B |
| Total Debt | 2.41B | 2.43B | 1.63B | 1.59B | 1.64B | 1.69B |
| Total Liabilities | 4.33B | 4.24B | 3.86B | 3.47B | 3.44B | 3.19B |
| Stockholders Equity | 7.30B | 7.21B | 6.89B | 6.48B | 5.98B | 5.73B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | -158.56M | 450.78M | 565.85M | 877.01M | -110.09M |
| Operating Cash Flow | 1.59B | 15.61M | 554.17M | 723.77M | 1.03B | 435.81M |
| Investing Cash Flow | -116.24M | 1.05B | -1.07B | 43.01M | -197.36M | -195.44M |
| Financing Cash Flow | -634.06M | 288.35M | -497.76M | -499.45M | -474.67M | -164.51M |
Tong Ren Tang Technologies Co Technical Analysis
Tong Ren Tang Technologies Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.41B | 7.19 | 10.85% | 6.14% | -20.64% | -25.39% | |
68 Neutral | $5.97B | 12.84 | 5.98% | 4.30% | 0.73% | -34.04% | |
66 Neutral | $7.32B | 14.20 | 13.22% | 4.07% | 24.13% | 4.29% | |
57 Neutral | HK$9.86B | 51.80 | 6.73% | ― | 23.37% | ― | |
54 Neutral | $11.63B | -40.67 | -1.26% | 3.56% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Co has renewed its Land Use Right Leasing Agreement with Tong Ren Tang Holdings, extending the lease for an additional three years from October 2025 to October 2028. This renewal allows the company to continue its operations at a prime location in Beijing, which is crucial for its business activities and development. The agreement is seen as beneficial due to the stable lease terms and cost savings from avoiding relocation, aligning with the company’s strategic interests and supporting its future business needs.
Tong Ren Tang Technologies Co has announced a Supplemental Trademark Licence Agreement with Tong Ren Tang Holdings, revising the terms and scope of its Current Trademark Licence Agreement. This includes changes to the subsidiaries entitled to use the ‘Tong Ren Tang’ tradename and trademarks, as well as adjustments to the annual caps for transactions under the agreement for 2026 and 2027. These revisions are in compliance with the Hong Kong Listing Rules and are significant for the company’s operational strategy and market positioning, as they impact the company’s licensing arrangements and financial planning.
Tong Ren Tang Technologies Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 30, 2025, to approve key agreements and appointments. The company seeks shareholder approval for the renewal of its Distribution Framework Agreement and Master Procurement Agreement with China Beijing Tong Ren Tang Group Co., Ltd., which will govern connected transactions from 2026 to 2028. Additionally, the appointment of Ms. Du Xin as a non-executive director is on the agenda, reflecting the company’s ongoing efforts to strengthen its governance and operational framework.
Tong Ren Tang Technologies Co. Ltd. announced the resignation of Mr. Chen Fei from his role as a non-executive director due to work adjustments, effective upon the election of a new director by shareholders. The company has proposed Ms. Du Xin as the new non-executive director, pending shareholder approval. Ms. Du, with a strong background in economics and management within the Tong Ren Tang Group, is expected to bring valuable expertise to the board, although her appointment will not include remuneration.
Tong Ren Tang Technologies Co. has announced the proposed renewal of its continuing connected transactions and the appointment of a new director. These developments are set to be discussed at an Extraordinary General Meeting (EGM) scheduled for December 30, 2025. The renewal of agreements and leadership changes are expected to impact the company’s operational strategies and governance, potentially influencing its market positioning and stakeholder relations.
Tong Ren Tang Technologies Co. Ltd. announced its unaudited financial results for the third quarter of 2025, reporting operating revenue of approximately RMB4,979.64 million and net profits attributable to shareholders of RMB416.26 million. The announcement highlights the company’s stable financial performance, with total assets recorded at RMB14,595.89 million, reflecting its strong market position and ongoing commitment to transparency for its stakeholders.
Tong Ren Tang Technologies Co. announced a delay in the dispatch of a circular related to the renewal of continuing connected transactions under the Distribution Framework Agreement and the Master Procurement Agreement. The delay, which pushes the dispatch date to on or before November 30, 2025, is due to the additional time needed to finalize the circular’s details and arrange its publication.
Tong Ren Tang Technologies Co, a joint stock company incorporated in China, has announced the renewal of its Distribution Framework Agreement and Master Procurement Agreement with Tong Ren Tang Holdings for a term of three years, from January 1, 2026, to December 31, 2028. These agreements, which involve continuing connected transactions, require independent shareholders’ approval due to the applicable percentage ratios exceeding 5%. An extraordinary general meeting will be convened to seek this approval, and an Independent Board Committee has been established to advise shareholders, with an independent financial adviser appointed to assist.
Tong Ren Tang Technologies Co. Ltd. announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has received a traditional medicine registration license from Cambodia’s Ministry of Health. This license allows the sale of ‘Tong Ren Tang Angong Niuhuang Wan’ in Cambodia, facilitating the expansion of the company’s distribution channels and market presence in the region. While this development is beneficial for market expansion, it is not expected to have a significant immediate impact on the company’s overall operations or performance.